ZI
Zim Laboratories Ltd (ZIMLAB)
₹147.80
Mkt cap
₹730 Cr
P/E ratio
353.00
P/B
2.71
Div yield
0.00%
ROE
1.59%
ROCE
4.76%
EPS (TTM)
₹0.42
Book value
₹55
52W range
59–160
Sector
Healthcare
Price history
Previous close
Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India [1]
NSE ZIMLABBSE 541400
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−7.52% from high₹148
₹59+149.20% from low₹160
Current
₹147.80
Prev close
₹148.82
Day
−0.69%
Price performance
1D
−0.55%
1W
+5.05%
1M
+12.02%
3M
+22.31%
6M
+47.84%
1Y
+100.03%
YTD
+109.85%
Financials
Revenue, profit & margin
P/E ratio
353.0×
ZIMLAB is 958% above the sector median of 33.4×
ZIMLAB353.0×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 85.83 | 96.29 | 117.86 | 81.82 | 92.14 | 96.33 | 108.73 | 71.76 | 88.71 | 108.66 | 105.27 | 94.18 | 105.45 | |
| YoY Sales growth | -13.65% | -4.64% | +11.81% | +21.32% | +7.35% | +0.04% | -7.75% | -12.30% | -3.72% | +12.80% | -3.18% | +31.24% | +18.87% | |
| Expenses | 76.50 | 84.75 | 102.21 | 73.78 | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 | 100.02 | |
| Operating Profit | 9.33 | 11.54 | 15.65 | 8.04 | 9.53 | 11.56 | 14.60 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 | 5.43 | |
| OPM % | 10.87% | 11.98% | 13.28% | 9.83% | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.60% | 5.15% | |
| Other Income | 1.42 | 1.11 | 1.53 | 1.00 | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.70 | 6.16 | 0.99 | 2.30 | |
| Interest | 1.22 | 1.70 | 2.28 | 2.86 | 2.89 | 2.73 | 2.91 | 3.30 | 3.16 | 3.43 | 3.31 | 3.64 | 3.94 | |
| Depreciation | 4.09 | 3.94 | 3.91 | 4.94 | 5.00 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.10 | 5.37 | 6.53 | |
| Profit before tax | 5.44 | 7.01 | 10.99 | 1.24 | 2.96 | 5.70 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 | -2.74 | |
| Tax % | 23.71% | 31.81% | 26.48% | 27.42% | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% | -25.18% | |
| Net Profit | 4.15 | 4.78 | 8.09 | 0.90 | 2.38 | 4.00 | 4.88 | -1.87 | -0.42 | 4.40 | 3.74 | -4.02 | -2.05 | |
| EPS in Rs | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 | -0.75 | -0.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202630.30%Promoter
Promoters30.30%0.06
FIIs0.17%0.14
DIIs1.19%0.15
Public68.35%0.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Zim Laboratories | ₹135.99 | 352.51 | 730 | 0.00% | −2 | −388.10% | 105 | +18.87% | 4.76% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports12
Concall transcripts35
TranscriptNov 2026PPTNov 2026RECNov 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024PPTAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 11 Nov - Transcript of Q2 & H1FY27 Earnings Conference CallAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 5 Nov - Audio recording of Q2 and H1 FY27 earnings conference call available on company website.Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Nov - The Newspaper Publication of financial results for the Quarter & Half yearly ended 30th September, 2026.Please Find Enclosed Earnings Presentation For Q2 & H1 FY27 4 Nov - Zim Labs released Q2&H1 FY27 presentation: revenue ₹1,054 Mn, EBITDA ₹77 Mn, TGA GMP approval, CAPA progress.Results - Financial Results For The Quarter And Half Year Ended 30Th September 2026 4 Nov






